N. Mariados

Comparison of fracture risk assessment tool score to bone mineral density for estimating fracture risk in patients with advanced prostate cancer on androgen deprivation therapy.

F. Saad, D. Albala, V. Mouraviev, 2014, Urology.

Hereditary cancer risk assessment and genetic testing in the community urology practice setting

H. Korman, T. Slavin, D. Iliev, 2022, The Prostate.

The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.

D. Albala, M. Emberton, V. Mouraviev, 2014, Reviews in urology.

Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases

S. Severi, O. Sartor, G. Procopio, 2019, The Prostate.

eRADicAte: A Prospective Evaluation Combining Radium‐223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration‐Resistant Prostate Cancer

N. Shore, N. Mariados, R. Tutrone, 2017, Clinical genitourinary cancer.

Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer.

P. Schellhammer, N. Shore, N. Mariados, 2020, Clinical genitourinary cancer.

Radium-223 (Ra-223) Re-Treatment (Re-tx): First Experience From an International, Multicenter, Prospective Study in Patients (Pts) With Castration-Resistant Prostate Cancer and Bone Metastases (mCRPC).

S. Severi, O. Sartor, P. Schwarzenberger, 2016, Clinical advances in hematology & oncology : H&O.

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases

S. Severi, Rui Li, O. Sartor, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy

A. Kishan, J. Sylvester, D. Low, 2023, JAMA oncology.